Tilray's Aphria RX Receives First Cannabis Cultivation License Under Germany's New Cannabis Act
Portfolio Pulse from Benzinga Newsdesk
Tilray Brands, Inc. (NASDAQ:TLRY) announced that its Germany-based facility, Aphria RX GmbH, has received the first cannabis cultivation license under Germany's new Cannabis Act. This license allows Aphria RX to cultivate and manufacture a wide range of medical cannabis, improving patient access to high-quality medical cannabis in Germany.
July 22, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tilray Brands, Inc. (NASDAQ:TLRY) has received the first cannabis cultivation license under Germany's new Cannabis Act, allowing its facility Aphria RX to cultivate and manufacture medical cannabis. This development is likely to enhance Tilray's market position in Germany and improve revenue prospects.
The new license allows Tilray's Aphria RX to cultivate and manufacture medical cannabis in Germany, which is a significant market. This is likely to enhance Tilray's market position and revenue prospects in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100